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OBJECTIVE — Despite the clinical importance of an accurate diagnosis in individuals with
monogenic forms of diabetes, restricted access to genetic testing leaves many patients with
undiagnosed diabetes. Recently, common variation near the HNF1 homeobox A (HNF1A) gene
was shown to inﬂuence C-reactive protein levels in healthy adults. We hypothesized that serum
levels of high-sensitivity C-reactive protein (hs-CRP) could represent a clinically useful biomar-
ker for the identiﬁcation of HNF1A mutations causing maturity-onset diabetes of the young
(MODY).
RESEARCH DESIGN AND METHODS — Serum hs-CRP was measured in subjects
with HNF1A-MODY (n  31), autoimmune diabetes (n  316), type 2 diabetes (n  240), and
glucokinase (GCK) MODY (n  24) and in nondiabetic individuals (n  198). The discrimina-
tive accuracy of hs-CRP was evaluated through receiver operating characteristic (ROC) curve
analysis,andperformancewascomparedwithstandarddiagnosticcriteria.Ourprimaryanalyses
excluded 11% of subjects in whom the single available hs-CRP measurement was 10 mg/l.
RESULTS — Geometric mean (SD range) hs-CRP levels were signiﬁcantly lower (P  0.009)
for HNF1A-MODY individuals, 0.20 (0.03–1.14) mg/l, than for any other group: autoimmune
diabetes 0.58 (0.10–2.75) mg/l, type 2 diabetes 1.33 (0.28–6.14) mg/l, GCK-MODY 1.01
(0.19–5.33) mg/l, and nondiabetic 0.48 (0.10–2.42) mg/l. The ROC-derived C-statistic for
discriminating HNF1A-MODY and type 2 diabetes was 0.8. Measurement of hs-CRP, either
alone or in combination with current diagnostic criteria, was superior to current diagnostic
criteria alone. Sensitivity and speciﬁcity for the combined criteria approached 80%.
CONCLUSIONS — Serum hs-CRP levels are markedly lower in HNF1A-MODY than in
other forms of diabetes. hs-CRP has potential as a widely available, cost-effective screening test
to support more precise targeting of MODY diagnostic testing.
Diabetes Care 33:1919–1924, 2010
M
utationsinthehepatocytenuclear
factor 1- (HNF1 homeobox A;
HNF-1; HNF1A) gene represent
the most common cause of maturity-
onset diabetes of the young (MODY) and
are estimated to account for 2% of all
diabetes (1). Demonstrating that an
HNF1Amutationisresponsiblefordiabe-
tes in a given individual has important
clinical implications for both patients and
their relatives: for example, in contrast to
typicaltype2diabetes,low-dosesulfonyl-
ureas rather than metformin should be
the ﬁrst-line treatment (2,3). Despite the
clinical value of an accurate molecular
diagnosis, many individuals with
HNF1A-MODY are never tested and are
consequently misclassiﬁed as having type
1 or type 2 diabetes.
The principal barriers to the imple-
mentation of systematic diagnostics for
monogenic forms of diabetes include the
high cost and restricted availability of ge-
netic testing. Currently, patients are typi-
cally selected for molecular testing on the
basis of nonspeciﬁc clinical features such
as age of onset, parental history of diabe-
tes (4), and/or a clinical presentation that
is otherwise atypical for the assumed eti-
ology (such as an apparent absence of
insulin resistance in an individual pre-
sumed to have type 2 diabetes [5]). How-
ever, the performance of these criteria is
such that it is difﬁcult to combine accept-
able levels of speciﬁcity and sensitivity.
Consequently, there would be consider-
able value in identifying additional
screening tools, which, in conjunction
with existing clinical and biochemical
markers,wouldassistselectionofindivid-
uals who merit further investigation, in-
cluding HNF1A sequencing. Because a
relative -cell defect is common to all
forms of diabetes, the best prospects for
identifying such a marker may be the ex-
trapancreaticmanifestationsofanHNF1A
mutation.
HNF1Aencodesthetranscriptionfac-
tor HNF-1, initially identiﬁed in the
liver, where it is involved in regulation of
a large number of genes (6) and also is
expressed in the pancreas, gut, and kid-
ney. There have been several previous at-
tempts to identify HNF1A-MODY
biomarkers, most based on candidates
initially highlighted by studies on Hnf1a
knockout mice (6,7). However, the can-
didates examined, including apolipopro-
tein M (8–10), aminoaciduria (11,12),
complement components (13), and gly-
cosuria (14–16), have either not demon-
strated sufﬁcient sensitivity and/or
speciﬁcity to warrant further evaluation
or have thus far not translated into a clin-
ically useful biomarker.
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studies have revealed that common vari-
ants mapping near the HNF1A gene on
chromosome 12q24 are associated with
small alterations in serum C-reactive pro-
tein (CRP) levels in healthy adults
(17,18). The presence of HNF-1 bind-
ing sites in the CRP promoter (19) sug-
gests that the effect on CRP is mediated
through altered regulation of HNF1A ex-
pression. Moreover, a loss of HNF1A
binding has been shown to result in a loss
of CRP expression (19). If so, it follows
thattherare,butlarge-effect,lossoffunc-
tion mutations in HNF1A responsible for
MODY might be expected to lead to more
substantial reductions in serum CRP lev-
els. This would be analogous to observa-
tions involving the glucokinase (GCK)
gene: although a common GCK promoter
variant is associated with a modest (0.06
mmol/l) effect on fasting plasma glucose
levels in healthy adults (20), rare patho-
genic mutations in GCK are responsible for
a far larger (2 mmol/l) increase (21).
We aimed to test whether individuals
with HNF1A-MODY have reduced serum
CRP levels compared with those in indi-
viduals with other forms of diabetes and
to establish whether CRP could be a use-
ful diagnostic marker.
RESEARCH DESIGN AND
METHODS— Thesubjectsincludedin
this study are more fully described in the
supplementary data (available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0288/DC1). In
brief, we included 31 individuals with
HNF1A-MODY, 24 with GCK-MODY,
275 with classic type 1 diabetes, 41 with
latent autoimmune diabetes of adult-
hood, 240 with young-onset type 2 dia-
betes (diagnosed up to 45 years of age),
and 198 nondiabetic individuals. The
study was approved by the Oxfordshire
Local Research Ethics Committee, and all
subjects gave informed consent.
Serum high-sensitivity CRP (hs-CRP)
levels were measured using a wide-range
latex-enhanced immunoturbidimetric as-
say on an ADVIA 2400 analyzer (Siemens
Healthcare Diagnostics, Frimley, U.K.),
with a quoted method linearity of 0.03–
160 mg/l. Imprecision, expressed as coef-
ﬁcients of variation, at concentrations
0.05 mg/l was 10% and at 23.5 mg/l
was 1%. GAD antibodies were mea-
suredbyaradioimmunoassayusinga
35S-
labeled full-length GAD65, with results
expressed in World Health Organization
(WHO) units per milliliter derived from a
standard curve calibrated from interna-
tional reference material (National Insti-
tute for Biological Standards and Control
code 97/550). Samples were considered
positive if they had levels above 14 WHO
units/ml (97.5th percentile of healthy
school-aged children) (22).
Analysis
hs-CRP values for all subjects were in-
spected. Means  SD for the two autoim-
mune groups (type 1 diabetes and latent
autoimmune diabetes of adulthood) were
very similar, so these were combined for
further analyses. Supplementary Fig. 1
(available in an online appendix) docu-
ments the distribution of individual hs-
CRP levels in all subjects. Median
(interquartile range) values for hs-CRP
are also reported in Table 1, along with
other clinical characteristics of the
groups. In line with previous studies
(23,24), we considered that hs-CRP values
10 mg/l were likely in many instances to
represent an acute inﬂammatory response
and, prior to any analysis, had decided to
exclude such values from our primary
analyses. From the 809 subjects with hs-
CRP values, 90 (11%) with hs-CRP 10
mg/l were removed: 3 (10%) with
HNF1A-MODY, 22 (7%) with autoim-
mune diabetes, and 53 (22%) with type 2
diabetes and 12 (6%) of the nondiabetic
subjects.
For subsequent analyses, all variables
were log-transformed. Differences be-
tween the hs-CRP values in the HNF1A-
MODY and other groups were evaluated
usingattest,bothbeforeandafteradjust-
ment for BMI (because BMI was corre-
lated with hs-CRP). Because certain
drugs,particularlystatinsandaspirin,can
lower CRP levels (25), we performed a
further analysis after removing subjects
treated with either. Other variables (sex,
age at sampling, A1C, duration of diabe-
tes,andethnicorigin)werenotassociated
with hs-CRP levels in our data and were
therefore not included as covariates. We
also examined whether the hs-CRP level
wasaffectedbythetypeofmutation(non-
sense versus missense) or the isoform of
HNF1A affected by missense mutations.
Finally,becausesomeofthesubjectswith
MODY were related to each other, we
sought to account for nonindependence in
twoways.First,wereanalyzeddatabyusing
only a single individual from each family
(either the proband or if he or she was not
available the youngest individual in the
family) and, second, by including family
membership as a covariate in the analysis.
The measurement of hs-CRP as a di-
agnostic test for HNF1A-MODY was ex-
amined by ROC curve analysis and
compared with standard clinical criteria.
Sensitivities and speciﬁcities were calcu-
lated from our data and then used to
model the effect of using hs-CRP with or
without clinical criteria as a screening test
for HNF1A mutations in a patient group
with apparent type 2 diabetes diagnosed
up to age 45 years (supplementary Table
2, available in an online appendix). For
this purpose, we assumed that 4% of the
group were subjects with misclassiﬁed
HNF1A-MODY, based on observations
we have made in a large undifferentiated
groupofyoung-onsettype2diabeticsub-
jects (K.R.O., M.I.M., unpublished data).
All statistical analysis was performed
withSPSS(version16).P0.05wascon-
sidered signiﬁcant.
RESULTS— The results conﬁrm our
hypothesis that hs-CRP levels are signiﬁ-
cantly lower in subjects with HNF1A-
MODY compared with those for all other
groups, including nondiabetic subjects
(Table 1, Fig. 1A). The geometric mean
(SD range) unadjusted hs-CRP value for
subjects with HNF1A-MODY (after ex-
clusion of those with hs-CRP 10 mg/l;
see RESEARCH DESIGN AND METHODS) was 0.20
(0.03–1.14) mg/l, compared with 1.33
(0.28–6.14) mg/l for those with type 2
diabetes, 0.58 (0.10–2.75) mg/l for those
with autoimmune diabetes, and 1.01
(0.19–5.33) mg/l for subjects with GCK-
MODY, and 0.48 (0.10–2.42) mg/l for
nondiabetic subjects (P  0.009 for all
pairwise comparisons with subjects with
HNF1A-MODY). The value for the other
diabetic groups combined was 0.81
(0.15–4.50) mg/l, signiﬁcantly greater
than that for the HNF1A-MODY group
(P  0.00003).
Use of statin and/or aspirin therapy
had negligible effects on the comparisons
with the HNF1A-MODY group (Table 1).
In the type 2 diabetic group, the hs-CRP
level was the same for the statin/aspirin
users as for the nonusers (P  0.27),
whereasinthetype1diabeticgroupthose
taking statins and/or aspirin had a higher
hs-CRPthannonusers(P0.004).Thus,
it seems unlikely that use of these drugs
would lower hs-CRP toward the range
seenintheHNF1A-MODYgroup.Incon-
trast, adjustment for BMI had a large im-
pact on the estimated means (Table 1)
and, given the correlation between BMI
andCRP(r
20.28,P10
6forcontrol
subjects), abolished much of the differ-
hs-CRP in subtypes of diabetes
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and other groups. However, the differ-
ences in hs-CRP levels between the
HNF1A-MODY and other groups were
preserved(P0.01).Estimatedmeanad-
justed hs-CRP (95% CI) levels for the
HNF1A-MODYgroupcomparedwiththe
other diabetic groups combined were
0.28 (0.16–0.49) vs. 0.82 (0.71–0.94)
mg/l (P  0.003). Reanalysis with ac-
counting for shared family membership
(see RESEARCH DESIGN AND METHODS) did not
alter the magnitude or signiﬁcance of the
most important between-group differ-
ences (e.g., using the probands only,
HNF1A-MODY vs. type 2 diabetes P 
7 	 10
6 and HNF1A-MODY vs. auto-
immune diabetes P  0.009). There was
no difference between the hs-CRP levels
seen in families segregating missense mu-
tations (11 families) compared with those
featuring a premature stop codon (8 fam-
ilies, P  0.6). Because all but two of the
missense mutations were in exons repre-
sented in all three HNF1A isoforms, we
could reach no conclusions concerning
the relationship between CRP levels and
the HNF1A isoform.
The differences in mean values be-
tween HNF1A-MODY and the other
groups are striking but do not necessarily
translateintoclinicalutility.Wetherefore
evaluated the performance of hs-CRP lev-
els as a potential diagnostic test for distin-
guishing HNF1A-MODY from other
kinds of diabetes (supplementary Tables
1 and 2). Figure 1B displays the (cumula-
tive) distribution of hs-CRP values for in-
dividuals in the different subject groups.
In our data, a diagnostic threshold value
of 0.4 mg/l (the vertical line on Fig. 1B)
equates to a sensitivity of 71% and speci-
ﬁcity of 77% for distinguishing HNF1A-
MODY from type 2 diabetes. These
ﬁguresarerevisedto65and82%,respec-
tively, if subjects with hs-CRP10 mg/l
are not excluded. Inclusion of individuals
with autoimmune diabetes and GCK-
MODY reduces the speciﬁcity of the hs-
CRP threshold of 0.4 mg/l to 63%. Use of
an hs-CRP threshold 0.4 mg/l improves
speciﬁcity (and would therefore reduce
the number of individuals with type 2 di-
abetes who might undergo “unnecessary”
HNF1Asequencing),butthiscomesatthe
expense of sensitivity (i.e., more individ-
uals with HNF1A-MODY are missed).
The consequences of using different hs-
CRP criteria on these measures of sensi-
tivity and sensitivity, in our data, are
illustrated in supplementary Table 1.
The ROC-derived C-statistic (a mea-
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justed hs-CRP levels was 0.80 for
distinguishing HNF1A-MODY from type
2 diabetes (Fig. 1C) and 0.75 for distin-
guishing HNF1A-MODY from all other
diabetes subtypes combined. We com-
pared the performance of hs-CRP (again
excluding those with hs-CRP10 mg/l)
to current diagnostic criteria including
age of diabetes onset 25 years and a
ﬁrst-degree family history of diabetes. In
our dataset, these existing criteria had
lower sensitivity (58%) than hs-CRP test-
ing, but they were highly speciﬁc for the
discrimination of HNF1A-MODY and
type 2 diabetes (only 6% of the latter met
these criteria). The combination of exist-
ing diagnostic criteria or an hs-CRP level
of 0.2 mg/l produced, in our dataset, a
sensitivity of 79% and speciﬁcity of 83%
for distinguishing HNF1A-MODY from
type 2 diabetes, a considerable improve-
ment in sensitivity (P  0.035) over tra-
ditional criteria alone with little loss of
Figure 1—The analyses included 28 subjects with HNF1A-MODY, 294 with autoimmune diabetes, 187 with type 2 diabetes, and 24 with
GCK-MODY and 198 nondiabetic control subjects. Values of hs-CRP 10 mg/l are excluded. A: Geometric mean hs-CRP levels for the different
groups; error bars show 95% CI. B: Cumulative percentage plot for hs-CRP levels in the different groups. The dotted reference line corresponds to a
hs-CRP value of 0.4 mg/l. hs-CRP levels are plotted on a log10 scale. C: ROC curve illustrating the capacity of hs-CRP to distinguish between
HNF1A-MODY and type 2 diabetes. The C-statistic (area under the curve) for this comparison is 0.8.
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of these criteria as a screening test for se-
lection of individuals for further investi-
gation would lead to sequencing of 20%
of type 2 diabetic subjects diagnosed up
to 45 years of age with a detection rate of
HNF1A mutations of 16% of those se-
quenced (supplementary Table 2).
CONCLUSIONS — We have shown
for the ﬁrst time that subjects with
HNF1A-MODY maintain substantially
lower levels of serum hs-CRP levels than
individuals with other forms of diabetes
or nondiabetic control subjects. By dem-
onstratingtheseeffectsofrarecodingmu-
tations in HNF1A, our ﬁndings therefore
extend recent observations that common
variants near HNF1A are associated with
CRP levels. Thus, our study conﬁrms that
the common variant associations are al-
most certainly mediated through alter-
ations in HNF1A transcription. However,
the observation that some individuals
with HNF1A-MODY had hs-CRP levels
10 mg/l (including one of 52 mg/l)
demonstrates that HNF1A haploinsufﬁ-
ciencyisnotsufﬁcienttopreventsubstan-
tialelevationinCRPlevels,presumablyas
part of an acute inﬂammatory response.
We have shown that as a standalone
diagnostic test to select individuals for
HNF1A-MODY sequencing, hs-CRP per-
formed reasonably well in our dataset,
with a C-statistic of 0.80 for differentiat-
ing HNF1A-MODY from young-onset
type 2 diabetes. In clinical use, it seems
likely that hs-CRP levels would be com-
bined with other clinical and biochemical
data within a broader diagnostic algo-
rithm. We have shown that such a com-
bination of clinical criteria and hs-CRP
can achieve sensitivities and speciﬁcities
of 80% (supplementary Table 1). We
are aware of the dangers of overﬁtting,
and clearly these performance metrics
need to be evaluated in independent
datasets. We also note that to take full
advantage of the sensitivity afforded by
this combination, molecular diagnostic
testing of 20% of those with the diag-
nosis of apparent type 2 diabetes who
were aged 45 years would be required
(supplementary Table 2). It is worth
emphasizing that in this study we fo-
cused on individuals with a relatively
early diagnosis of type 2 diabetes on the
basis that these individuals constitute
the group in which the diagnostic dif-
ferentiation from HNF1A-MODY is
most pertinent.
One point for discussion is how val-
uesoutsidethenormalrangefortheassay
should be handled. By removing all indi-
vidualswithhs-CRP10mg/l,wesought
to avoid the loss of discriminatory accu-
racyassociatedwithwhatweassumetobe
acutely elevated hs-CRP levels. Our cur-
rent recommendation would be for indi-
viduals with elevated CRP levels to have a
repeat measure some weeks later, allow-
ing any acute inﬂammatory response to
subside. Because our study did not in-
clude serial measurements of hs-CRP, fu-
ture studies will be needed to explore this
particular issue. It is entirely plausible
that the low-grade chronic elevation of
CRP, which is characteristic of type 2 di-
abetes,wouldenhancethediscriminatory
performance of repeated over single hs-
CRP measures.
Although we included reasonably
largecollectionsofsubjectswithHNF1A-
MODY and GCK-MODY, the very low
prevalence of HNF4A-MODY means that
subjectswiththisformofMODYwerenot
available for comparison. HNF4A-MODY
presents with a -cell phenotype very
similar to that of HNF1A-MODY, but
many of the extrapancreatic manifesta-
tions are distinct (4). Because the CRP
promoter lacks any HNF-4 binding
sites, it seems probable that hs-CRP levels
in subjects with HNF4A-MODY will not
be reduced: if future studies conﬁrm this
theory, hs-CRP levels may provide useful
diagnostic differentiation between
HNF1A and HNF4A-MODY.
Insummary,wehaveshownthatsub-
jects with pathogenic mutations in
HNF1A have signiﬁcantly lower serum
levels of hs-CRP than those with other
typesofdiabetes.Althoughtheseﬁndings
require validation in independent data-
sets and extension to other rarer subtypes
of MODY, hs-CRP emerges from this
study as the most promising diagnostic
biomarker for HNF1A-MODY identiﬁed
to date. Because hs-CRP estimation is al-
readywidelyavailableatlowcostinmany
routine pathology services, it should be
relatively easy to incorporate this biomar-
ker into diagnostic pathways. We expect
this inclusion to lead to better targeting of
molecular diagnostic testing for mono-
genic forms of diabetes and for conse-
quent improvements in detection rates to
result in more effective treatment of this
currently underdiagnosed condition.
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